Insight

The safety, efficacy, and pharmacokinetics of deulorlatinib in ALK-positive NSCLC

IASLC/LinkedIn

Jun 21, 2025, 05:18

The safety, efficacy, and pharmacokinetics of deulorlatinib in ALK-positive NSCLC

International Association for the Study of Lung Cancer shared a post on LinkedIn:

“In this study, Zhao et al. evaluated the safety, efficacy, and pharmacokinetics of deulorlatinib in ALK-positive NSCLC. The results demonstrated its potential to become a new treatment option in this patient population.”

Title: Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b Trial

Authors: Shen Zhao, Huaqiang Zhou, Nong Yang, Zhehai Wang, Wenjian Jin, Yuxiang Ma, Jinhui Xue, Xingya Li, Yunpeng Liu, Rui Meng, Jianying Zhou, Ying Cheng, Yongsheng Wang, Zhuang Yu, Yu Cao, Yuanyuan Zhao, Yan Huang, Wenfeng Fang, Yang Zhang, Shaodong Hong, Bo Wu, Yanxia Shi, Jingrong Cao, Mingyan Xu, Xiaoni Zhang, Longyu Hu, Bo Peng, Yunpeng Yang, Li Zhang, Hongyun Zhao

Read the Full Article.

NSCLC

Bo Peng Bo Wu cancer Hongyun Zhao Huaqiang Zhou Jianying Zhou Jingrong Cao Jinhui Xue Li Zhang Longyu Hu Mingyan Xu Nong Yang OncoDaily Oncology Rui Meng Shaodong Hong Shen Zhao Wenfeng Fang Wenjian Jin Xiaoni Zhang Xingya Li Yan Huang Yang Zhang Yanxia Shi Ying Cheng Yongsheng Wang Yu Cao Yuanyuan Zhao Yunpeng Liu Yunpeng Yang Yuxiang Ma Zhehai Wang Zhuang Yu

Cardio-Oncology in Focus: How Chemotherapy Can Harm Heart Health

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect